Assertio Holdings, Inc.
Customers
3
3 disclosed
Suppliers
1
1 disclosed
Largest customer
45%
COR · FY to 2025-12-31
Named-customer revenue
$102.1M
3 customers · FY to 2025-12-31
Latest period
Mar 31, 2026
10-Q filed 2026-05-13
Customers 3
Companies Assertio Holdings, Inc. discloses as major customers, as a share of Assertio Holdings, Inc. revenue. 3 active, 0 lapsed.
| Company | % of Assertio Holdings, Inc. revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| COR Distributor Cencora, Inc. |
45% | $53.4M | FY 2025-12-31 | +5.0pp | Active | 10-K 2026-03-16 |
Cencora 45 % 40 % 44 % 33 % | ||||||
| MCK Distributor MCKESSON CORP |
31% | $36.8M | FY 2025-12-31 | +1.0pp | Active | 10-K 2026-03-16 |
McKesson Corporation 31 % 30 % 39 % 42 % | ||||||
| CAH Distributor CARDINAL HEALTH INC |
10% | $11.9M | FY 2025-12-31 | +2.0pp | Active | 10-K 2026-03-16 |
Cardinal Health 10 % 8 % 10 % 6 % | ||||||
Suppliers 1
Companies that disclose Assertio Holdings, Inc. as a major customer, as a share of their own revenue. 1 active, 0 lapsed.
| Company | % of their revenue | Est. $ from Assertio Holdings, Inc. | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics, Inc. |
Named | — | 3M 2026-03-31 | — | Active | 10-Q 2026-05-13 |
The Company also entered into a long-term supply agreement with Assertio for Sympazan pursuant to which the Company is the exclusive sole worldwide manufacturer and supplier of the product and will receive manufacturing fees from Assertio for the product through the expiration of such supply agreement. | ||||||
Unnamed major customers
Disclosed without names in the fiscal year ending 2025-12-31. Identities are not inferred.
Alerts are coming
Get an email when Assertio Holdings, Inc.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.